Kiniksa(US:KNSA)2026-01-12 22:22Revenue and Growth - ARCALYST® net product revenue for 2025 was $677.5 million, representing approximately 62% year-over-year growth from $417.0 million in 2024[4] - Kiniksa expects ARCALYST net product revenue for 2026 to be between $900 million and $920 million[7] Patient Treatment and Usage - As of the end of 2025, approximately 18% of the 14,000 multiple-recurrence patients were actively on ARCALYST treatment[7] - More than 4,150 prescribers have written ARCALYST prescriptions since its launch[7] - Average total duration of ARCALYST therapy in recurrent pericarditis is approaching 3 years[7] Clinical Trials and Development - KPL-387 Phase 2 recurrent pericarditis data is expected in the second half of 2026[2] - KPL-1161 Phase 1 trial is planned to initiate by the end of 2026[2] Financial Position - Cash balance increased to $414.1 million as of December 31, 2025, with no debt[7] - Gross-to-net was 8.4% for 2025, down from 9.8% in 2024, impacted by the Inflation Reduction Act[7] - Kiniksa expects its current operating plan to remain cash flow positive on an annual basis[7]